Jump to main content

Knopp Biosciences

Knopp Biosciences

Knopp Biosciences seeks to discover, develop, and deliver breakthrough medicines for urgent unmet medical needs. Our goal is to accelerate and advance treatment, change the course of devastating diseases, and improve the lives of patients and their families.

Bold science. Breakthrough medicine.

Home Slide 5
Products and Programs

Clinical Programs: Inflammation and Hematology

Knopp is advancing dexpramipexole as an anti-inflammatory therapeutic based on extensive preclinical and clinical evidence of its activity in modulating white blood cells known as eosinophils.

Hematology Discovery Program

The selective arrest of eosinophil maturation using orally available drugs presents the potential for novel treatments for inflammatory disease. Knopp is focused on identifying and modulating the molecular mechanisms underlying eosinophil differentiation.

KCNQ2 Preclinical Program

Knopp is advancing novel agents to activate a key ion channel in nerve cells, targeting a devastating genetic mutation associated with neonatal encephalopathy, as well as epilepsy and neuropathic pain.

Mitochondrial Discovery Program

The disruption of cellular bioenergetics has emerged as a common factor in pathways leading to cell death in ALS, Parkinson's, and other neurodegenerative disorders. Knopp's research is focused on small molecule modulators to improve mitochondrial efficiency.